| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Institut für Pharmakologie [K. C. Z., A-A. W., K. S.] and Institut für Pathologie [M. S., H. E. G.], Heinrich-Heine-Universität, 40225 Düsseldorf, and Institut für Pathologie, Klinikum Aschaffenburg, 63739 Aschaffenburg [F. B.], Germany
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
In the present study, we have determined the expression of COX-2 in SCC and ADC of the esophagus. The functional role of COX-2-derived PGs for the regulation of cell proliferation and apoptosis was studied in two different esophageal cell lines.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Patients.
Tissue samples were collected retrospectively from 172 patients with SCC of the esophagus who underwent esophagectomy between January 1978 and December 1994. No preoperative radio- or chemotherapy had been performed. Of the patients, 133 were male and 39 were female. The median age was 58 years (range, 24–82). Additionally, 27 patients who underwent esophageal resection without prior radio- or chemotherapy between January 1987 and December 1997 due to ADC of the esophagus were included. All ADCs arose in the setting of Barrett’s esophagus, as shown by the histological demonstration of metaplastic and/or dysplastic Barrett’s mucosa adjacent to the ADCs. Of these patients, 26 were male and 1 was female. The median age was 62 years (range, 36–81).
Pathological Review of the Surgical Samples.
The esophagectomy specimens were fixed in 4% buffered formaldehyde, embedded in paraffin, sectioned, and stained with H&E. The pT and pN categories were determined according to the criteria proposed by the Union Internationale Contre le Cancer (27)
. Tumor type and the grade of tumor differentiation were determined according to the criteria proposed by the WHO (28)
. Tumor size was defined as the largest diameter of the tumor. Of the 172 SCCs, 29 tumors were categorized as pT1 (16.9%), 33 as pT2 (19.2%), 105 as pT3 (61.0%), and 5 as pT4 (2.9%). Among all cases, 83 tumors were in category pN0 (48.3%) and 89 tumors were in category pN1 (51.7%). Of all tumors, 19 were graded as G1 (11.1%), 70 as G2 (40.7%), 52 as G3 (30.2%), and 31 as G4 (18.0%); one hundred eighteen tumors had a maximum diameter of 
5 cm (68.6%), whereas 54 tumors were >5 cm (31.4%).
Of the 27 ADCs, 8 tumors were categorized as pT1 (29.6%), 5 as pT2 (18.5%), and 14 as pT3 (51.9%). Among all cases, 11 tumors were in category pN0 (40.7%) and 16 tumors were in category pN1 (59.3%). Of all tumors, 12 were graded as G2 (44.4%), 13 as G3 (48.2%), and 2 as G4 (7.4%); fourteen tumors had a maximum diameter of 5 cm (51.9%), whereas 13 tumors were >5 cm (48.1%).
Cell Lines.
OSC-1 and OSC-2 are permanent cell lines derived from two poorly differentiated SCCs of the esophagus; they have been established and characterized in our laboratory (29)
. The cell lines were maintained in DMEM (Life Technologies, Inc., Eggenstein, Germany) supplemented with FCS (10%), penicillin (100 units/ml), and streptomycin (0.1 mg/ml).
COX-2 Immunohistochemistry.
COX-2 protein expression was investigated in SCC, in ADC, and in the cell lines. For each of the carcinomas, one representative block including central and peripheral portions of the tumor was selected. As control, five samples of nonmalignant esophageal squamous epithelium from tumor-free resection margins of the esophagectomy specimens and five samples of metaplastic Barrett’s mucosa situated adjacent to the ADC were selected for COX-2 immunohistochemistry. After microwave pretreatment in citrate buffer (pH 6.0) for 15 min at 750 W, slides were incubated overnight at 4°C with the monoclonal COX-2 antibody at a dilution of 1:50. After a second incubation with a biotin-conjugated antimouse antibody, slides were incubated with an avidin-biotin-peroxidase reagent (ABC Kit, "Elite-Vectastain"; Vector Laboratories, Burlingame, CA). Reaction products were visualized by immersing slides in diaminobenzidine tetrachloride and finally counterstained with hemalaun. Positive staining of normal esophageal squamous epithelium and of smooth muscle cells within the esophageal wall provided an internal positive control for COX-2 staining. The immunohistochemical expression of COX-2 in the tumor cells was examined by one senior pathologist (M. S.) using light microscopy. The percentage of positive tumor cells was determined semiquantitatively by assessing the whole tumor section, and each sample was assigned to one of the following categories: 0 (0–4%), 1 (5–24%), 2 (25–49%), 3 (50–74%), or 4 (75–100%). The intensity of immunostaining was determined as 0 (negative), 1+ (weak), and 2+ (strong). Intensity of immunostaining was judged relative to smooth muscle cells within the sample, which were designated arbitrarily as 2+. Additionally, an immunoreactive score was calculated by multiplication of the percentage of positive cells and the staining intensity, as proposed by Krajewska et al. (30)
. In the case of heterogeneous staining intensities within one sample, each component was scored independently, and the results were summed. For example, a specimen containing 25% tumor cells with strong intensity (1 x 2+ = 2), 25% tumor cells with weak intensity (1 x 1+ = 1), and 50% tumor cells without immunoreactivity received a score of 2 + 1 + 0 = 3.
When the primary antibody was replaced by an irrelevant isotype-matched monoclonal mouse antibody at the same dilution as the COX-2 antibody (1:50), no immunostaining was detectable in any of the investigated tissues.
RT-PCR.
Total cellular RNA was prepared from cell lines OSC-1 and OSC-2 using a modified Trizol extraction technique (Life Technologies, Inc.). Total RNA (1 µg) was converted into cDNA with murine leukemia virus reverse transcriptase at 42°C for 15 min and denaturated at 95°C for 10 min. A PCR was performed using the following primers (0.15 µM): human COX-1 (481-bp fragment), sense 5'-CCGTCCTGCTCGCGGACCCAGGGGC-3', antisense 5'-AAGCGGCGGGCCAGGAGCTGGGCA-3'; human COX-2 (421-bp fragment), sense 5'-AATGAGTACCGAAAATTC-3', antisense 5'-CATCTAGTCCGGAGCGGGAAG-3'. The PCR was carried out using the GeneAmp RNA PCR kit (Perkin-Elmer Corp., Branchburg, NJ). The samples were predenaturated for 2 min at 94°C, and the cycle profile (40 cycles) was as follows: denaturation at 95°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 1.5 min. PCR products were separated by 1.5% agarose gel electrophoresis and ethidium bromide staining. Fragments were identified by fragment size and restriction analysis using ClaI, HaeIII, HinfI, NcoI, and PstI restriction enzymes.
Negative controls of COX-1 and COX-2 RT-PCR, which contained no reverse transcriptase, showed no PCR products.
Western Blotting.
For Western blot analysis, tumor tissue from seven different SCCs, one sample of normal esophageal squamous epithelium, and the two SCC cell lines were used. Surgical specimens from the primary tumor and normal esophageal mucosa were washed in ice-cold physiological saline, immediately frozen in liquid nitrogen and stored at -80°C before analysis. The esophageal tissues or the cells were homogenized in radioimmunoprecipitation assay buffer [150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, and 50 mM Tris (pH 8.0) supplemented with protease inhibitors leupeptin (1 µg/ml), aprotinin (1 µg/ml), pepstatin (0.5 µg/ml)] and phenylmethylsulfonylfluoride (100 µg/ml), and sonicated. The sample was then heated for 5 min to 95°C and centrifuged (13,000 rpm, 10 min, 4°C). Protein concentration was measured with the Bio-Rad DC Kit (Bio-Rad Laboratories), according to the manufacturer’s instructions. Proteins (100 µg) were separated by SDS (8%)-PAGE and transferred to Immobilion-P membranes (Millipore Inc., Bedford, MA). For immunodetection of the COX-protein, the membranes were probed with COX-2 antibodies (1:1000) or COX-1 antibodies (1:1000), followed by incubation with peroxidase-conjugated secondary antibody (antimouse IgG; 1:3000, Dianova, Hamburg, Germany). COX proteins were visualized by enhanced chemiluminescence (Amersham Buchler, Braunschweig, Germany) using Kodak X-Omat films (Eastman Kodak, Rochester, NY). The specificities of the COX-1 antibody and the COX-2 antibody were tested using COX-1 protein from ram seminal vesicles (Cayman Chemicals) and human recombinant COX-2 protein (Calbiochem). In this analysis, no cross-reactivity of the two antibodies were found (data not shown).
Measurement of PG Production.
For the measurement of PG production, cell cultures were grown in DMEM containing penicillin (100 units/ml) and streptomycin (0.1 mg/ml) in a humified atmosphere of 5% CO2 and 95% air at 37°C. Subconfluent cells were treated with the COX inhibitors flosulide or NS-398 at different concentrations. PG formation was measured in terms of bicyclo-PGE2 (31)
and 6-keto-PGF1
(32)
by RIA in aliquots of the supernatants.
Measurement of Proliferation.
The proliferation of the esophageal tumor cell lines was determined using the cell proliferation kit II (Boehringer Mannheim, Mannheim, Germany). Tumor cells were incubated with flosulide and NS-398 at different concentrations for 48 h in DMEM containing FCS (10%), penicillin (100 units/ml), and streptomycin (0.1 mg/ml). After this time, the XTT labeling mixture was added, followed by 4 h of incubation and measurement of absorbance at 490 nm (reference wavelength, 595 nm).
Assessment of Mitotic and Apoptotic Indices.
The esophageal tumor cells were seeded in chamber slides (Nalge Nunc Int., Naperville, IL) and incubated for 48 h with flosulide at different concentrations in a humified atmosphere of 5% CO2 and 95% air at 37°C. Cells were fixed in 3% paraformaldehyde and 1% NP40 and H&E stained. Mitotic and apoptotic tumor cells were counted (blinded for the treatment the cells had received) in 10 randomly selected microscopic fields (corresponding to a total of at least 1000 tumor cells) under high power magnification (x400), using a quadratic reticle with 25 squares of 4 mm2 inserted in the ocular lens (33)
. Mitotic cells and apoptotic cells were identified by standard criteria (34
, 35)
. The mitotic index and apoptotic index/case were expressed as percentages of the mean number of mitotic figures or apoptotic bodies/100 intact tumor cells.
Transmission Electron Microscopic Examination for Apoptotic Cells.
For transmission electron microscopy, OSC-1 cells and OSC-2 cells were seeded on glass coverslips and incubated for 48 h with flosulide in different concentrations. Subsequently, the cells were fixed in situ by exposure to 2.5% sodium cacodylate-buffered glutaraldehyde solution (0.1 M, pH 7.4) before Epon-embedding in situ. Thin sections were contrasted with uranyl acetate and lead citrate and subsequently examined with a Zeiss EM 109 transmission electron microscope.
Statistical Analysis.
Statistical analysis of the correlation between COX-2 expression in the tumors and clinicopathological parameters was performed by means of a two-sided Fisher’s exact test. For the comparison of COX-2 expression between SCC and ADC, the Kruskal-Wallis test was used. The effects of exposure of esophageal cancer cell lines to COX-2-inhibiting compounds were analyzed by means of unpaired Student’s t test. Ps <0.05 were considered significant.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. Additionally, COX-2 immunoreactivity was found in smooth muscle cells (Fig. 1b)
, in fibroblasts, and in endothelial cells. Among the carcinomas, 156 of 172 SCCs (90.7%) exhibited cytoplasmatic immunoreactivity for COX-2 in the tumor cells (Fig. 1c)
, whereas 16 carcinomas (9.3%) were completely negative. Among COX-2-positive carcinomas, the percentage and staining intensity of positive tumor cells varied markedly between different tumors. The immunoreactive score ranged between 1 and 8 (median, 3). The details of expression patterns regarding the percentage of positive cells, staining intensity, and immunoreactive score are presented in Table 1
. The results of the immunohistochemical investigations were confirmed by Western blot analysis, where all samples of SCCs investigated showed expression of the COX-2 protein. The expression of COX-2 in some carcinomas was enhanced as compared with the normal mucosa (Fig. 2)
.
|
|
|
). Immunohistochemical investigation of COX-1 in paraffin-embedded tumor samples did not reveal reliable staining results (data not shown).
Expression of COX-2 in Metaplastic Barrett’s Mucosa and in ADCs.
Metaplastic Barrett’s mucosa showed no immunoreactivity for COX-2 (Fig. 1d)
, whereas COX-2 immunostaining again was observed in smooth muscle cells, in fibroblasts, and in endothelial cells. Of the 27 ADCs, 21 carcinomas (77.8%) showed cytoplasmatic immunoreactivity for COX-2 (Fig. 1e)
and 6 carcinomas (22.2%) were completely negative. As in the case of SCC, there was marked intertumoral heterogeneity in terms of staining intensity and percentage of positive cells among COX-2-positive ADC. The immunoreactive score ranged between 1 and 8 (median, 3). The details of expression patterns are presented in Table 1
. No significant differences were found when COX-2 expression among SCC and ADC was compared in terms of staining intensity, percentage of positive cells, or immunoreactive score.
Correlation between COX-2 Immunostaining in SCC and ADC and Other Pathological Parameters.
For correlation analysis, SCC and ADC were dichotomized at the median immunoreactive score (3 in both groups of tumors) into one group with weak or no COX-2 expression and in one group with strong COX-2 expression. Among SCC, local lymph node metastasis was found more frequently among tumors with low COX-2 expression (58.5%) than among tumors with strong COX-2 expression (37.0%; P = 0.013). No correlations were found between COX-2 expression and pT category or tumor differentiation. Among ADC, no significant correlations were found between COX-2 immunoreactivity and pT category, pN category, or tumor differentiation.
Expression of COX-1 and COX-2, PG Synthesis, and Its Inhibition in Tumor Cell Lines.
The two tumor cell lines (OSC-1 and OSC-2) showed a different expression of the COX isoforms. OSC-2 expressed COX-2 mRNA (Fig. 3A)
and COX-2 protein (Fig. 3B)
, but showed no COX-1 mRNA and protein expression. In contrast, OSC-1 expressed high levels of COX-1 protein, but showed only a very weak COX-2 protein expression (Fig. 3B)
. Additionally, immunostaining for COX-2 was found only in OSC-2 cells (Fig. 1F)
. To evaluate the functional activity of cyclooxygenases in the cell lines, we measured PG production by RIA. The cell line OSC-2 synthesized high amounts of PGE2 (143 ± 11 ng/ml) and also 6-keto-PGF1 (761 ± 9 pg/ml), whereas OSC-1 showed considerable lower PG synthesis (248 ± 13 pg/ml PGE2 and 34 ± 6 pg/ml 6-keto-PGF1; Fig. 4, A and B)
. To study the relevance of COX-2 for PG synthesis, we measured the inhibition of PGE2 generation by the COX-2-selective inhibitors flosulide (36)
and NS-398 (37)
. Flosulide (1 nM-100 µM) caused a concentration-dependent and finally complete inhibition of PGE2 production in the OSC-2 cell line, whereas no effect on PG formation was observed in the OSC-1 cells (Fig. 5)
. Similar results were obtained with NS-398 (1 nM-100 µM), which inhibited PG synthesis less potently than flosulide, but also significantly at a concentration of 1 nM in the OSC-2 cells (Fig. 5)
.
|
|
|
. The results of the XTT assay were confirmed by light microscopic examination of flosulide (1 nM-100 µM)-treated OSC-1 and OSC-2 cells. Because of the higher specificity for COX-2 and the stronger antiproliferative effect of flosulide, the effect on apoptosis was examined only with this compound. Treatment with 1 nM flosulide completely suppressed mitotic activity of OSC-2 cells, whereas mitotic activity of OSC-1 cells remained unchanged (data not shown). Additionally, a marked induction of apoptosis among OSC-2 cells, due to treatment with flosulide, was observed (Figs. 7
and 8
). Transmission electron microscopic examination of OSC-1 cells and OSC-2 cells, treated by various concentrations of flosulide (1 nM-100 µM), confirmed massive induction of apoptosis among OSC-2 cells as compared with untreated controls, whereas no effect on apoptosis was observed in OSC-1 cells (data not shown).
|
|
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Our immunohistochemical analysis showed marked intertumoral heterogeneity in COX-2 expression, ranging from tumors with few weakly positive cancer cells to tumors with apparent COX-2 overexpression. Intertumoral heterogeneity has also been reported in previous studies on COX-2 expression in colon cancer (13, 14, 15) . However, in these studies, the interest has not focused on this phenomenon, either because very small numbers of tumor samples have been investigated, or because tissue extracts with a mixture of neoplastic cells and nonneoplastic stromal cells were analyzed. In this type of analysis, however, it is hardly possible to determine whether the detected signal actually stems from the neoplastic tumor cells. The possibility for obtaining signals for COX-2 expression by means of Northern blot or Western blot analysis in a tumor with neoplastic cells that are actually devoid of COX-2 has to be taken into consideration because we and others (15) found that COX-2 is present in a variety of nonneoplastic stromal cells.
Taking these considerations into account, we have to cautiously interpret our Western blot analysis concerning COX-1 expression. Thus, we were able to show COX-1 expression at similar levels in a limited number of esophageal SCCs and in nonmalignant esophageal epithelium. However, examination of a larger number of paired samples of tumor tissue and nonmalignant mucosa, as well as examination of normal mucosa from persons without esophageal cancer in future studies will be necessary to exactly determine the status of COX-1 in normal esophageal mucosa and in esophageal cancer.
The function of COX-2 in tumor development and progression in vivo is not known. The most obvious possibility is that overexpression of COX-2 leads to high levels of PGs in tumor tissues. A hypothesis that is supported by the finding of elevated levels of PGs in cancer tissues, compared with corresponding normal tissues (18 , 38) . PGs, produced by COX-2, may subsequently facilitate tumor progression by acting as differentiation and growth factors, as immunosuppressors, and as angiogenic agents (39, 40, 41) . Additionally, it has been shown that elevated PGE2 levels in COX-2 overexpressing cells correlate with the metastatic potential of the cancer cells, which can be reduced in a dose-dependent manner by COX inhibitors (20) . On the other hand, there is also evidence that NSAIDs might exert their antineoplastic effect by a PG-independent pathway, and that the COX-2 enzyme itself may promote cancer development and progression (42) . Thus, NSAIDs suppressed proliferative activity in colon cancer cells devoid of cyclooxygenases and PGs (43) . Moreover, the sulfone derivative of the NSAID sulindac inhibits the growth of colon cancer cells without repressing PG synthesis (44) . Tsujii and DuBois(19) found reduced susceptibility to apoptosis and overexpression of the antiapoptotic oncoprotein Bcl-2 among rat intestinal cells that overexpressed COX-2. Recently, it has been shown that exposure of colon carcinoma cells to NSAIDs induced hypophosphorylation of the retinoblastoma tumor suppressor protein as well as a down-regulation of multiple proliferation-promoting cyclins and cyclin-dependent kinases (45) .
Apart from the demonstration of the presence of COX-2 in esophageal cancer, the present study suggests an important function of COX-2 in this tumor type. We have shown that selective inhibition of COX-2 in esophageal cancer cells induces apoptotic cell death and reduces proliferative activity, and that these effects correlate with the inhibition of PG synthesis. The specificity of this effect is underlined by the finding that only in the cell line OSC-2, which shows constitutively high expression of COX-2, the selective inhibitors exert their antiproliferative and apoptosis-inducing effect, whereas no effect was observed in the cell line OSC-1, which is characterized by high levels of COX-1 but only weak expression of COX-2. The finding that flosulide and NS-398 did not inhibit production of prostanoids in OSC-1 cells points to their high specificity for COX-2. Similar results have been reported by other authors, who found no inhibition of COX-1 by flosulide or NS-398 even at concentrations of 100 µM (46 , 47 , 36) .
The apparent difference between the cell lines correspond to our immunohistological analysis of COX-2 expression in esophageal SCC and ADC, which also showed marked intertumoral heterogeneity. Therefore, the significance of COX-2 probably varies between different tumors. We cannot conclude from our in vitro data whether the antiproliferative and proapoptotic effect of COX-2 inhibitors on esophageal cancer cells is exclusively mediated through the inhibition of PG synthesis or if other mechanisms are also involved. However, our data may provide an explanation for epidemiological studies indicating that the long-term intake of COX inhibitors substantially reduces the incidence of esophageal cancer. The results of our immunohistological analyses indicate that COX-2 is equally expressed in esophageal SCCs and ADCs. The pharmacological inhibition of COX-2 may, therefore, be effective in the two main types of esophageal cancer. The response of individual tumors to exposure of COX-2 inhibiting compounds in vivo, however, awaits further evaluation, especially because the level of COX-2 expression varies substantially between different tumors.
In conclusion, our study provides evidence that COX-2 is expressed in the majority of esophageal SCCs and ADCs and that COX-2-derived PGs are involved in the progression of esophageal cancer. By analogy to the situation in colorectal cancer, COX-2 may be a new target in the chemoprevention and chemotherapy of esophageal carcinoma.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported by the "Forschungsgruppe Herz-Kreislauf e. V." The data presented in this paper are part of a Ph.D. thesis at the Heinrich-Heine-Universität, Düsseldorf, Germany. 
2 To whom requests for reprints should be addressed, at the Institut für Pathologie, Heinrich-Heine-Universität, Moorenstr. 5, 40225 Düsseldorf, Germany. Phone: 49-211-811-8487; Fax: 49-211-811-8353.
3 The abbreviations used are: NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase; SCC, squamous cell carcinoma; ADC, adenocarcinoma; PG, prostaglandin; PGE2, PG E2; XTT, 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt; RT-PCR, reverse transcription-PCR.
Received 7/ 2/98. Accepted 10/30/98.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  L. Yu, W. K. K. Wu, Z. J. Li, Q. C. Liu, H. T. Li, Y. C. Wu, and C. H. Cho Enhancement of Doxorubicin Cytotoxicity on Human Esophageal Squamous Cell Carcinoma Cells by Indomethacin and 4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via Inhibiting P-Glycoprotein Activity Mol. Pharmacol., June 1, 2009; 75(6): 1364 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K R Fareed, P Kaye, I N Soomro, M Ilyas, S Martin, S L Parsons, and S Madhusudan Biomarkers of response to therapy in oesophago-gastric cancer Gut, January 1, 2009; 58(1): 127 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cui, L.-Y. Xu, Z.-Y. Shen, Q. Tao, S.-Y. Gao, Z. Lv, Z.-P. Du, W.-K. Fang, and E.-M. Li NGALR Is Overexpressed and Regulated by Hypomethylation in Esophageal Squamous Cell Carcinoma Clin. Cancer Res., December 1, 2008; 14(23): 7674 - 7681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yu, W. K. K. Wu, Z. J. Li, H. P. S. Wong, E. K. K. Tai, H. T. Li, Y. C. Wu, and C. H. Cho E Series of Prostaglandin Receptor 2-Mediated Activation of Extracellular Signal-Regulated Kinase/Activator Protein-1 Signaling Is Required for the Mitogenic Action of Prostaglandin E2 in Esophageal Squamous-Cell Carcinoma J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 258 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sadeghi, C. J. Bain, N. Pandeya, P. M. Webb, A. C. Green, D. C. Whiteman, and for the Australian Cancer Study Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1169 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Adachi, Y. Tajima, T. Kuroki, T. Mishima, A. Kitasato, N. Tsuneoka, and T. Kanematsu Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters Carcinogenesis, April 1, 2008; 29(4): 830 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Ferguson, C. P. Wild, L. A. Anderson, S. J. Murphy, B. T. Johnston, L. J. Murray, R.G. P. Watson, J. McGuigan, J. V. Reynolds, and L. J. Hardie Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Gene Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 727 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F.G. de Maat, C. J.H. van de Velde, N. Umetani, P. de Heer, H. Putter, A. Q. van Hoesel, G. A. Meijer, N. C. van Grieken, P. J.K. Kuppen, A. J. Bilchik, et al. Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer J. Clin. Oncol., November 1, 2007; 25(31): 4887 - 4894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Si, X. Fu, J. Behar, J. Wands, D. G. Beer, R. F. Souza, S. J. Spechler, D. Lambeth, and W. Cao NADPH Oxidase NOX5-S Mediates Acid-induced Cyclooxygenase-2 Expression via Activation of NF-{kappa}Bin Barrett's Esophageal Adenocarcinoma Cells J. Biol. Chem., June 1, 2007; 282(22): 16244 - 16255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R C Fitzgerald Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut, December 1, 2006; 55(12): 1810 - 1820. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jimeno, M. L. Amador, P. Kulesza, X. Wang, B. Rubio-Viqueira, X. Zhang, A. Chan, J. Wheelhouse, H. Kuramochi, K. Tanaka, et al. Assessment of celecoxib pharmacodynamics in pancreatic cancer Mol. Cancer Ther., December 1, 2006; 5(12): 3240 - 3247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Wang, T.-T. Wu, E. Resetkova, H. Wang, A. M. Correa, W. L. Hofstetter, S. G. Swisher, J. A. Ajani, A. Rashid, S. R. Hamilton, et al. Expression of Annexin A1 in Esophageal and Esophagogastric Junction Adenocarcinomas: Association with Poor Outcome Clin. Cancer Res., August 1, 2006; 12(15): 4598 - 4604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Y.Y. Fong, Y. Jiang, and J. L. Farber Zinc deficiency potentiates induction and progression of lingual and esophageal tumors in p53-deficient mice Carcinogenesis, July 1, 2006; 27(7): 1489 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Anderson, B. T. Johnston, R.G. P. Watson, S. J. Murphy, H. R. Ferguson, H. Comber, J. McGuigan, J. V. Reynolds, and L. J. Murray Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-Metaplasia-Adenocarcinoma Sequence. Cancer Res., May 1, 2006; 66(9): 4975 - 4982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kaul, S. C. Verma, M. Murakami, K. Lan, T. Choudhuri, and E. S. Robertson Epstein-Barr Virus Protein Can Upregulate Cyclo-Oxygenase-2 Expression through Association with the Suppressor of Metastasis Nm23-H1 J. Virol., February 1, 2006; 80(3): 1321 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Secchiero, E. Barbarotto, A. Gonelli, M. Tiribelli, C. Zerbinati, C. Celeghini, C. Agostinelli, S. A. Pileri, and G. Zauli Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells Am. J. Pathol., December 1, 2005; 167(6): 1599 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Xi, S. E. Baldus, U. Warnecke-Eberz, J. Brabender, S. Neiss, R. Metzger, F. C. Ling, H. P. Dienes, E. Bollschweiler, S. Moenig, et al. High Cyclooxygenase-2 Expression Following Neoadjuvant Radiochemotherapy Is Associated with Minor Histopathologic Response and Poor Prognosis in Esophageal Cancer Clin. Cancer Res., December 1, 2005; 11(23): 8341 - 8347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-G. Liu, L. Zhang, Y. Jiang, D. Chatterjee, C. M. Croce, K. Huebner, and L. Y.Y. Fong Modulation of Gene Expression in Precancerous Rat Esophagus by Dietary Zinc Deficit and Replenishment Cancer Res., September 1, 2005; 65(17): 7790 - 7799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H.A. von Rahden, H. J. Stein, F. Puhringer, I. Koch, R. Langer, G. Piontek, J. R. Siewert, H. Hofler, and M. Sarbia Coexpression of Cyclooxygenases (COX-1, COX-2) and Vascular Endothelial Growth Factors (VEGF-A, VEGF-C) in Esophageal Adenocarcinoma Cancer Res., June 15, 2005; 65(12): 5038 - 5044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Mollace, C. Muscoli, E. Masini, S. Cuzzocrea, and D. Salvemini Modulation of Prostaglandin Biosynthesis by Nitric Oxide and Nitric Oxide Donors Pharmacol. Rev., June 1, 2005; 57(2): 217 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-Y. Lo, K.-Y. Lam, P. P Leung, and J. M Luk High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma Eur. J. Endocrinol., April 1, 2005; 152(4): 545 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Oyama, T. Fujimura, I. Ninomiya, T. Miyashita, S. Kinami, S. Fushida, T. Ohta, and M. Koichi A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats Carcinogenesis, March 1, 2005; 26(3): 565 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Lagergren Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut, March 1, 2005; 54(suppl_1): i1 - i5. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Dannenberg, S. M. Lippman, J. R. Mann, K. Subbaramaiah, and R. N. DuBois Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention J. Clin. Oncol., January 10, 2005; 23(2): 254 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Y. Y. Fong, L. Zhang, Y. Jiang, and J. L. Farber Dietary Zinc Modulation of COX-2 Expression and Lingual and Esophageal Carcinogenesis in Rats J Natl Cancer Inst, January 5, 2005; 97(1): 40 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Chang, H.-L. Wu, J.-J. Lee, P.-H. Lee, H.-H. Chang, L.-J. Hahn, B.-R. Lin, Y.-J. Chen, and J.-H. Jeng The Induction of Prostaglandin E2 Production, Interleukin-6 Production, Cell Cycle Arrest, and Cytotoxicity in Primary Oral Keratinocytes and KB Cancer Cells by Areca Nut Ingredients Is Differentially Regulated by MEK/ERK Activation J. Biol. Chem., December 3, 2004; 279(49): 50676 - 50683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-P. Lin, S. K. Kulp, P.-H. Tseng, Y.-T. Yang, C.-C. Yang, C.-S. Chen, and C.-S. Chen Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms Mol. Cancer Ther., December 1, 2004; 3(12): 1671 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Nam, K.-B. Hahm, S.-Y. Oh, M. Yeo, S.-U. Han, B. Ahn, Y.-B. Kim, J. S. Kang, D. D. Jang, K.-H. Yang, et al. The Selective Cyclooxygenase-2 Inhibitor Nimesulide Prevents Helicobacter pylori-Associated Gastric Cancer Development in a Mouse Model Clin. Cancer Res., December 1, 2004; 10(23): 8105 - 8113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Basu, L. B. Pathangey, T. L. Tinder, M. LaGioia, S. J. Gendler, and P. Mukherjee Cyclooxygenase-2 Inhibitor Induces Apoptosis in Breast Cancer Cells in an In vivo Model of Spontaneous Metastatic Breast Cancer Mol. Cancer Res., November 1, 2004; 2(11): 632 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Cheong, K. Ivory, J. Doleman, M.L. Parker, M. Rhodes, and I.T. Johnson Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest Carcinogenesis, October 1, 2004; 25(10): 1945 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-C. Huang, S.-T. Chan, T.-L. Yang, C.-C. Tzeng, and C.-C. Chen Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel {alpha}-methylene-{gamma}-butyrolactone derivatives Carcinogenesis, October 1, 2004; 25(10): 1925 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Abdalla, P. Lao-Sirieix, M. R. Novelli, L. B. Lovat, I. R. Sanderson, and R. C. Fitzgerald Gastrin-Induced Cyclooxygenase-2 Expression in Barrett's Carcinogenesis Clin. Cancer Res., July 15, 2004; 10(14): 4784 - 4792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hamoui, J. H. Peters, S. Schneider, K. Uchida, D. Yang, D. Valboehmer, J. A. Hagen, S. R. DeMeester, T. R. DeMeester, K. Danenberg, et al. Increased Acid Exposure in Patients With Gastroesophageal Reflux Disease Influences Cyclooxygenase-2 Gene Expression in the Squamous Epithelium of the Lower Esophagus Arch Surg, July 1, 2004; 139(7): 712 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Davydova, L. P. Le, T. Gavrikova, M. Wang, V. Krasnykh, and M. Yamamoto Infectivity-Enhanced Cyclooxygenase-2-Based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma Treatment Cancer Res., June 15, 2004; 64(12): 4319 - 4327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sussmann, M. Sarbia, J. Meyer-Kirchrath, R.M. Nusing, K. Schror, and J.W. Fischer Induction of Hyaluronic Acid Synthase 2 (HAS2) in Human Vascular Smooth Muscle Cells by Vasodilatory Prostaglandins Circ. Res., March 19, 2004; 94(5): 592 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Shaik, A. Chatterjee, and M. Singh Effect of a Selective Cyclooxygenase-2 Inhibitor, Nimesulide, on the Growth of Lung Tumors and Their Expression of Cyclooxygenase-2 and Peroxisome Proliferator- Activated Receptor-{gamma} Clin. Cancer Res., February 15, 2004; 10(4): 1521 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Su, J.-Y. Shih, M.-L. Yen, Y.-M. Jeng, C.-C. Chang, C.-Y. Hsieh, L.-H. Wei, P.-C. Yang, and M.-L. Kuo Cyclooxygenase-2 Induces EP1- and HER-2/Neu-Dependent Vascular Endothelial Growth Factor-C Up-Regulation: A Novel Mechanism of Lymphangiogenesis in Lung Adenocarcinoma Cancer Res., January 15, 2004; 64(2): 554 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T J Jang, S K Min, J D Bae, K H Jung, J I Lee, J R Kim, and W S Ahn Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dysplasia and Barrett's metaplasia induced by duodenal contents reflux Gut, January 1, 2004; 53(1): 27 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Nathoo, G H Barnett, and M Golubic The eicosanoid cascade: possible role in gliomas and meningiomas J. Clin. Pathol., January 1, 2004; 57(1): 6 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Choy and L. Milas Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance? J Natl Cancer Inst, October 1, 2003; 95(19): 1440 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-T. Kuo, K.-C. Chow, Y.-C. Wu, C.-S. Lin, H.-W. Wang, W.-Y. Li, and L.-S. Wang Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma Ann. Thorac. Surg., September 1, 2003; 76(3): 909 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Minter, J. W. Eveson, S. Huntley, D. J. E. Elder, and A. Hague The Cyclooxygenase 2-selective Inhibitor NS398 Inhibits Proliferation of Oral Carcinoma Cell Lines by Mechanisms Dependent and Independent of Reduced Prostaglandin E2 Synthesis Clin. Cancer Res., May 1, 2003; 9(5): 1885 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sawaoka, D. A. Dixon, J. A. Oates, and O. Boutaud Tristetraprolin Binds to the 3'-Untranslated Region of Cyclooxygenase-2 mRNA. A POLYADENYLATION VARIANT IN A CANCER CELL LINE LACKS THE BINDING SITE J. Biol. Chem., April 11, 2003; 278(16): 13928 - 13935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. V. N. Lord, J. M. Park, K. Wickramasinghe, S. R. DeMeester, S. Oberg, D. Salonga, J. Singer, J. H. Peters, K. D. Danenberg, T. R. DeMeester, et al. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 246 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Zweifel, T. W. Davis, R. L. Ornberg, and J. L. Masferrer Direct Evidence for a Role of Cyclooxygenase 2-derived Prostaglandin E2 in Human Head and Neck Xenograft Tumors Cancer Res., November 15, 2002; 62(22): 6706 - 6711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pouliot, M.-E. Fiset, M. Masse, P. H. Naccache, and P. Borgeat Adenosine Up-Regulates Cyclooxygenase-2 in Human Granulocytes: Impact on the Balance of Eicosanoid Generation J. Immunol., November 1, 2002; 169(9): 5279 - 5286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kohen and A. Nyska Invited Review: Oxidation of Biological Systems: Oxidative Stress Phenomena, Antioxidants, Redox Reactions, and Methods for Their Quantification Toxicol Pathol, October 1, 2002; 30(6): 620 - 650. [Abstract] [PDF]
|
|
|
|
|
|
Z. G. Li, T. Hong, Y. Shimada, I. Komoto, A. Kawabe, Y. Ding, J. Kaganoi, Y. Hashimoto, and M. Imamura Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol Carcinogenesis, September 1, 2002; 23(9): 1531 - 1536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Vaughan, A. R. Kristal, P. L. Blount, D. S. Levine, P. C. Galipeau, L. J. Prevo, C. A. Sanchez, P. S. Rabinovitch, and B. J. Reid Nonsteroidal Anti-inflammatory Drug Use, Body Mass Index, and Anthropometry in Relation to Genetic and Flow Cytometric Abnormalities in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 745 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Carlton, R. Gopalakrishnan, A. Gupta, B. W. Liston, S. Habib, M. A. Morse, and G. D. Stoner Piroxicam Is an Ineffective Inhibitor of N-Nitrosomethylbenzylamine-induced Tumorigenesis in the Rat Esophagus Cancer Res., August 1, 2002; 62(15): 4376 - 4382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tamura, S. Sebastian, S. Yang, B. Gurates, K. Ferrer, H. Sasano, K. Okamura, and S. E. Bulun Up-regulation of Cyclooxygenase-2 Expression and Prostaglandin Synthesis in Endometrial Stromal Cells by Malignant Endometrial Epithelial Cells. A PARACRINE EFFECT MEDIATED BY PROSTAGLANDIN E2 AND NUCLEAR FACTOR-kappa B J. Biol. Chem., July 12, 2002; 277(29): 26208 - 26216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. F. Orengo, J. Gerguis, R. Phillips, A. Guevara, A. T. Lewis, and H. S. Black Celecoxib, a Cyclooxygenase 2 Inhibitor as a Potential Chemopreventive to UV-Induced Skin Cancer: A Study in the Hairless Mouse Model Arch Dermatol, June 1, 2002; 138(6): 751 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Edwards, S. P. Faux, S. M. Plummer, K. R. Abrams, R. A. Walker, D. A. Waller, and K. J. O'Byrne Cyclooxygenase-2 Expression Is a Novel Prognostic Factor in Malignant Mesothelioma Clin. Cancer Res., June 1, 2002; 8(6): 1857 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Half, X. M. Tang, K. Gwyn, A. Sahin, K. Wathen, and F. A. Sinicrope Cyclooxygenase-2 Expression in Human Breast Cancers and Adjacent Ductal Carcinoma in Situ Cancer Res., March 1, 2002; 62(6): 1676 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Niki, T. Kohno, S. Iba, Y. Moriya, Y. Takahashi, M. Saito, A. Maeshima, T. Yamada, Y. Matsuno, M. Fukayama, et al. Frequent Co-Localization of Cox-2 and Laminin-5 {gamma}2 Chain at the Invasive Front of Early-Stage Lung Adenocarcinomas Am. J. Pathol., March 1, 2002; 160(3): 1129 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Denda, W. Kitayama, A. Murata, H. Kishida, Y. Sasaki, O. Kusuoka, T. Tsujiuchi, M. Tsutsumi, D. Nakae, H. Takagi, et al. Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide Carcinogenesis, February 1, 2002; 23(2): 245 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Fritsche, S. J. Baek, L. M. King, D. C. Zeldin, T. E. Eling, and D. A. Bell Functional Characterization of Cyclooxygenase-2 Polymorphisms J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 468 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Stoner and A. Gupta Etiology and chemoprevention of esophageal squamous cell carcinoma Carcinogenesis, November 1, 2001; 22(11): 1737 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Saukkonen, O. Nieminen, B. van Rees, S. Vilkki, M. Harkonen, M. Juhola, J.-P. Mecklin, P. Sipponen, and A. Ristimaki Expression of Cyclooxygenase-2 in Dysplasia of the Stomach and in Intestinal-type Gastric Adenocarcinoma Clin. Cancer Res., July 1, 2001; 7(7): 1923 - 1931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shono, P. J. Tofilon, J. M. Bruner, O. Owolabi, and F. F. Lang Cyclooxygenase-2 Expression in Human Gliomas: Prognostic Significance and Molecular Correlations Cancer Res., June 1, 2001; 61(11): 4375 - 4381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Murono, H. Inoue, T. Tanabe, I. Joab, T. Yoshizaki, M. Furukawa, and J. S. Pagano Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells PNAS, May 24, 2001; (2001) 121016998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Sales, A. A. Katz, M. Davis, S. Hinz, R. P. Soeters, M. D. Hofmeyr, R. P. Millar, and H. N. Jabbour Cyclooxygenase-2 Expression and Prostaglandin E2 Synthesis Are Up-Regulated in Carcinomas of the Cervix: A Possible Autocrine/Paracrine Regulation of Neoplastic Cell Function via EP2/EP4 Receptors J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2243 - 2249. [Abstract] [Full Text]
|
|
|
|
|
|
Z. Li, Y. Shimada, A. Kawabe, F. Sato, M. Maeda, I. Komoto, T. Hong, Y. Ding, J. Kaganoi, and M. Imamura Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor Carcinogenesis, April 1, 2001; 22(4): 547 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Biramijamal, A. Allameh, P. Mirbod, H.-J. Groene, R. Koomagi, and M. Hollstein Unusual Profile and High Prevalence of p53 Mutations in Esophageal Squamous Cell Carcinomas from Northern Iran Cancer Res., April 1, 2001; 61(7): 3119 - 3123. [Abstract] [Full Text]
|
|
|
|
|
|
C. A. Eads, R. V. Lord, K. Wickramasinghe, T. I. Long, S. K. Kurumboor, L. Bernstein, J. H. Peters, S. R. DeMeester, T. R. DeMeester, K. A. Skinner, et al. Epigenetic Patterns in the Progression of Esophageal Adenocarcinoma Cancer Res., April 1, 2001; 61(8): 3410 - 3418. [Abstract] [Full Text]
|
|
|
|
|
|
M. Li, X. Wu, and X.-C. Xu Induction of Apoptosis in Colon Cancer Cells by Cyclooxygenase-2 Inhibitor NS398 through a Cytochrome c-dependent Pathway Clin. Cancer Res., April 1, 2001; 7(4): 1010 - 1016. [Abstract] [Full Text]
|
|
|
|
|
|
S Chariyalertsak, V Sirikulchayanonta, D Mayer, A Kopp-Schneider, G Furstenberger, F Marks, and K Muller-Decker Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma Gut, January 1, 2001; 48(1): 80 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Souza, K. Shewmake, D. G. Beer, B. Cryer, and S. J. Spechler Selective Inhibition of Cyclooxygenase-2 Suppresses Growth and Induces Apoptosis in Human Esophageal Adenocarcinoma Cells Cancer Res., October 1, 2000; 60(20): 5767 - 5772. [Abstract] [Full Text]
|
|
|
|
|
|
R. Masunaga, H. Kohno, D. K. Dhar, S. Ohno, M. Shibakita, S. Kinugasa, H. Yoshimura, M. Tachibana, H. Kubota, and N. Nagasue Cyclooxygenase-2 Expression Correlates with Tumor Neovascularization and Prognosis in Human Colorectal Carcinoma Patients Clin. Cancer Res., October 1, 2000; 6(10): 4064 - 4068. [Abstract] [Full Text]
|
|
|
|
|
|
A. Kirschenbaum, D. R. Liotta, S. Yao, X.-H. Liu, A. P. Klausner, P. Unger, E. Shapiro, I. Leav, and A. C. Levine Immunohistochemical Localization of Cyclooxygenase-1 and Cyclooxygenase-2 in the Human Fetal and Adult Male Reproductive Tracts J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3436 - 3441. [Abstract] [Full Text]
|
|
|
|
|
|
T. Joki, O. Heese, D. C. Nikas, L. Bello, J. Zhang, S.-K. Kraeft, N. T. Seyfried, T. Abe, L. B. Chen, R. S. Carroll, et al. Expression of Cyclooxygenase 2 (COX-2) in Human Glioma and in Vitro Inhibition by a Specific COX-2 Inhibitor, NS-398 Cancer Res., September 1, 2000; 60(17): 4926 - 4931. [Abstract] [Full Text]
|
|
|
|
|
|
J. J. Y. Sung, W. K. Leung, M. Y. Y. Go, K. F. To, A. S. L. Cheng, E. K. W. Ng, and F. K. L. Chan Cyclooxygenase-2 Expression in Helicobacter pylori-Associated Premalignant and Malignant Gastric Lesions Am. J. Pathol., September 1, 2000; 157(3): 729 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takahashi, M. Mutoh, T. Kawamori, T. Sugimura, and K. Wakabayashi Altered expression of {beta}-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis Carcinogenesis, July 1, 2000; 21(7): 1319 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Li, R. Lotan, B. Levin, E. Tahara, S. M. Lippman, and X.-C. Xu Aspirin Induction of Apoptosis in Esophageal Cancer: A Potential for Chemoprevention Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 545 - 549. [Abstract] [Full Text]
|
|
|
|
|
|
A.-L. Hsu, T.-T. Ching, D.-S. Wang, X. Song, V. M. Rangnekar, and C.-S. Chen The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2 J. Biol. Chem., April 6, 2000; 275(15): 11397 - 11403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Bauer, L. D. Dwyer-Nield, and A. M. Malkinson High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors Carcinogenesis, April 1, 2000; 21(4): 543 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shamma, H. Yamamoto, Y. Doki, J. Okami, M. Kondo, Y. Fujiwara, M. Yano, M. Inoue, N. Matsuura, H. Shiozaki, et al. Up-Regulation of Cyclooxygenase-2 in Squamous Carcinogenesis of the Esophagus Clin. Cancer Res., April 1, 2000; 6(4): 1229 - 1238. [Abstract] [Full Text]
|
|
|
|
|
|
M. T. Yip-Schneider, D. S. Barnard, S. D. Billings, L. Cheng, D. K. Heilman, A. Lin, S. J. Marshall, P. L. Crowell, M. S. Marshall, and C. J. Sweeney Cyclooxygenase-2 expression in human pancreatic adenocarcinomas Carcinogenesis, February 1, 2000; 21(2): 139 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-J. Yuan, A. K. Mandal, Z. Zhang, and A. B. Mukherjee Transcriptional Regulation of Cyclooxygenase-2 Gene Expression: Novel Effects of Nonsteroidal Anti-Inflammatory Drugs Cancer Res., February 1, 2000; 60(4): 1084 - 1091. [Abstract] [Full Text]
|
|
|
|
|
|
H. Y. Lim, H. J. Joo, J. H. Choi, J. W. Yi, M. S. Yang, D. Y. Cho, H. S. Kim, D. K. Nam, K. B. Lee, and H. C. Kim Increased Expression of Cyclooxygenase-2 Protein in Human Gastric Carcinoma Clin. Cancer Res., February 1, 2000; 6(2): 519 - 525. [Abstract] [Full Text]
|
|
|
|
|
|
M. Kondo, H. Yamamoto, H. Nagano, J. Okami, Y. Ito, J. Shimizu, H. Eguchi, A. Miyamoto, K. Dono, K. Umeshita, et al. Increased Expression of COX-2 in Nontumor Liver Tissue Is Associated with Shorter Disease-free Survival in Patients with Hepatocellular Carcinoma Clin. Cancer Res., December 1, 1999; 5(12): 4005 - 4012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Mohammed, D. W. Knapp, D. G. Bostwick, R. S. Foster, K. N. M. Khan, J. L. Masferrer, B. M. Woerner, P. W. Snyder, and A. T. Koki Expression of Cyclooxygenase-2 (COX-2) in Human Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder Cancer Res., November 1, 1999; 59(22): 5647 - 5650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Molina, M. Sitja-Arnau, M. G. Lemoine, M. L. Frazier, and F. A. Sinicrope Increased Cyclooxygenase-2 Expression in Human Pancreatic Carcinomas and Cell Lines: Growth Inhibition by Nonsteroidal Anti-Inflammatory Drugs Cancer Res., September 1, 1999; 59(17): 4356 - 4362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Okami, H. Yamamoto, Y. Fujiwara, M. Tsujie, M. Kondo, S. Noura, S. Oshima, H. Nagano, K. Dono, K. Umeshita, et al. Overexpression of Cyclooxygenase-2 in Carcinoma of the Pancreas Clin. Cancer Res., August 1, 1999; 5(8): 2018 - 2024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Du Plessis, E. Dietzsch, M. Van Gele, N. Van Roy, P. Van Helden, M. I. Parker, D. K. Mugwanya, M. De Groot, M. P. Marx, M. J. Kotze, et al. Mapping of Novel Regions of DNA Gain and Loss by Comparative Genomic Hybridization in Esophageal Carcinoma in the Black and Colored Populations of South Africa Cancer Res., April 1, 1999; 59(8): 1877 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-T. Lin, R.-C. Lee, P.-C. Yang, F.-M. Ho, and M.-L. Kuo Cyclooxygenase-2 Inducing Mcl-1-dependent Survival Mechanism in Human Lung Adenocarcinoma CL1.0 Cells. INVOLVEMENT OF PHOSPHATIDYLINOSITOL 3-KINASE/Akt PATHWAY J. Biol. Chem., December 21, 2001; 276(52): 48997 - 49002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Murono, H. Inoue, T. Tanabe, I. Joab, T. Yoshizaki, M. Furukawa, and J. S. Pagano Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells PNAS, June 5, 2001; 98(12): 6905 - 6910. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
